Uwe Platzbecker Selected Research

Myelodysplastic Syndromes (Myelodysplastic Syndrome)

11/2022	Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts.
5/2022	Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies.
1/2022	Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
1/2022	Case Report: Personalized Therapeutical Approaches with Lenalidomide in Del(5q): A Case Series.
1/2022	Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.
1/2022	Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes.
12/2021	Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial.
11/2021	Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscape.
11/2021	Targeting health-related quality of life in patients with myelodysplastic syndromes - Current knowledge and lessons to be learned.
10/2021	Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Uwe Platzbecker Research Topics

Disease

93	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 11/2022 - 05/2008
65	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2022 - 06/2002
33	Neoplasms (Cancer) 01/2022 - 08/2007
18	Leukemia 11/2021 - 08/2003
16	Acute Promyelocytic Leukemia 12/2021 - 01/2010
14	Anemia 12/2021 - 01/2016
13	Graft vs Host Disease (Graft-Versus-Host Disease) 10/2022 - 05/2007
10	Thrombocytopenia (Thrombopenia) 05/2022 - 08/2012
9	Iron Overload 10/2020 - 11/2008
8	Residual Neoplasm 01/2021 - 11/2009
7	Fatigue 01/2020 - 02/2013
6	Primary Myelofibrosis (Myelosclerosis) 01/2022 - 02/2018
6	Multiple Myeloma 08/2021 - 08/2006
5	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 05/2022 - 02/2012
5	Lymphoma (Lymphomas) 08/2021 - 08/2006
5	Infections 01/2021 - 09/2002
5	Hemorrhage 12/2020 - 06/2014
4	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 09/2008
4	Disease Progression 01/2020 - 02/2015
4	Febrile Neutropenia 12/2018 - 05/2011
3	Neutropenia 05/2022 - 04/2016
3	Inflammation (Inflammations) 11/2021 - 01/2021
3	Thrombosis (Thrombus) 08/2021 - 05/2016
3	Weight Loss (Weight Reduction) 03/2021 - 07/2006
3	Diarrhea 01/2020 - 01/2016
3	Cytopenia 09/2019 - 09/2008
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 06/2011 - 01/2002
2	Systemic Mastocytosis 11/2022 - 12/2021
2	Bronchiolitis Obliterans Syndrome 10/2022 - 09/2008
2	Pathologic Complete Response 01/2022 - 01/2020
2	Peripheral Nervous System Diseases (PNS Diseases) 11/2021 - 02/2018
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021 - 01/2021
2	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 09/2020 - 09/2008
2	Nausea 01/2020 - 01/2016
2	Melanoma (Melanoma, Malignant) 09/2019 - 12/2018
2	Acute Kidney Injury (Acute Renal Failure) 01/2018 - 01/2009
2	Pneumonia (Pneumonitis) 01/2018 - 04/2016
2	Osteoporosis 12/2016 - 04/2013
2	Refractory Anemia 12/2015 - 02/2012
2	Chromosome Aberrations (Chromosome Abnormalities) 08/2012 - 05/2008
2	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 01/2009 - 09/2008

Drug/Important Bio-Agent (IBA)

22	Lenalidomide (CC 5013)FDA Link 01/2022 - 05/2008
18	Azacitidine (5 Azacytidine)FDA Link 05/2022 - 09/2010
11	Tretinoin (Retinoic Acid)FDA LinkGeneric 12/2021 - 07/2013
10	Arsenic Trioxide (Trisenox)FDA Link 12/2021 - 01/2010
10	HematinicsIBA 01/2021 - 11/2014
9	Decitabine FDA Link 01/2021 - 05/2011
8	luspaterceptIBA 11/2022 - 01/2017
8	IronIBA 04/2021 - 08/2014
5	Pharmaceutical PreparationsIBA 05/2022 - 03/2012
5	eltrombopag FDA Link 12/2018 - 08/2012
4	LigandsIBA 11/2021 - 08/2003
4	Biological ProductsIBA 11/2021 - 02/2012
4	Erythropoietin FDA Link 01/2020 - 11/2014
3	Phosphotransferases (Kinase)IBA 05/2022 - 09/2019
3	N- (cyanomethyl)- 4- (2- ((4- (4- morpholinyl)phenyl)amino)- 4- pyrimidinyl)benzamideIBA 01/2022 - 02/2018
3	Hemoglobins (Hemoglobin)IBA 11/2021 - 01/2021
3	Bendamustine Hydrochloride FDA Link 08/2021 - 01/2021
3	Rituximab (Mabthera)FDA Link 08/2021 - 09/2008
3	Biomarkers (Surrogate Marker)IBA 12/2020 - 12/2012
3	Ferritins (Ferritin)IBA 08/2020 - 11/2008
3	Busulfan (Busulfex)FDA Link 01/2020 - 03/2010
3	fludarabineIBA 01/2020 - 09/2008
3	ON 01910IBA 09/2019 - 04/2016
3	romiplostim FDA Link 03/2018 - 06/2014
3	Imatinib Mesylate (Gleevec)FDA Link 09/2017 - 01/2002
3	SteroidsIBA 02/2016 - 09/2008
2	avapritinibIBA 11/2022 - 12/2021
2	Proteins (Proteins, Gene)FDA Link 12/2021 - 10/2020
2	CPX-351IBA 10/2021 - 01/2020
2	Janus Kinase InhibitorsIBA 04/2021 - 02/2018
2	cc-486IBA 01/2021 - 01/2016
2	Chimeric Antigen ReceptorsIBA 01/2021 - 01/2021
2	Monoclonal AntibodiesIBA 01/2021 - 09/2008
2	RNA Splicing FactorsIBA 10/2019 - 03/2013
2	MethyltransferasesIBA 12/2017 - 12/2012
2	Thalidomide (Thalomid)FDA Link 01/2016 - 06/2012
2	MicroRNAs (MicroRNA)IBA 04/2015 - 03/2013
2	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 04/2015 - 06/2012
2	Dexamethasone (Maxidex)FDA LinkGeneric 06/2012 - 04/2009
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2012 - 09/2004
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2010 - 08/2007
2	Caspase 8 (Caspase-8)IBA 09/2004 - 08/2003
2	AcidsIBA 08/2003 - 01/2002

Therapy/Procedure

48	Therapeutics 06/2022 - 01/2002
27	Stem Cell Transplantation 10/2022 - 07/2002
23	Hematopoietic Stem Cell Transplantation 10/2022 - 01/2009
20	Drug Therapy (Chemotherapy) 01/2022 - 07/2006
16	Cell Transplantation 01/2022 - 09/2008
12	Erythrocyte Transfusion 12/2021 - 11/2008
11	Transplantation 10/2022 - 05/2007
7	Homologous Transplantation 01/2020 - 09/2002
4	Salvage Therapy 01/2021 - 09/2008
4	Platelet Transfusion (Blood Platelet Transfusions) 03/2018 - 06/2014
3	Induction Chemotherapy 01/2018 - 02/2012
3	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 11/2008 - 05/2007
2	Immunotherapy 11/2021 - 11/2011
2	Radiotherapy 01/2020 - 07/2006
2	Drug Tapering 02/2018 - 05/2008
2	Ligation 04/2012 - 09/2004